K K Jensen1, C Grønhøj1, D H Jensen1, C von Buchwald1. 1. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: The incidence of human papillomavirus-induced (HPV+) head and neck squamous cell carcinoma (HNSCC), that is, especially oropharyngeal cancers (OPSCC), is increasing, and a significant proportion of patients encounter disease progression. A simple and sensitive test to identify patients with progression is an unmet need. OBJECTIVE OF REVIEW: To systematically review the literature and carry out a meta-analysis of studies, investigating circulating HPV-DNA as a biomarker for disease progression in patients with HNSCC. TYPE OF REVIEW: A systematic review and meta-analysis. SEARCH STRATEGY: PubMed, EMBASE and the Cochrane Library were systematically searched for articles published in English from January 1980 to November 2017. Search terms used were related to HPV, cancer sites, blood-based biomarkers and terms for specific use settings. EVALUATION METHOD: Articles reviewed and selected by authors and data on study design, demographic variables, location, HPV status, number of pre-treatment blood tests, number of post-treatment blood tests, blood HPV status and number of recurrences and length of follow-up were extracted. A meta-analysis of HPV-DNA as a diagnostic test for recurrence by means of a hierarchical summary receiver operating curve (HSROC) model was performed. RESULTS: We identified 5 studies (n = 600 subjects) examining circulating HPV-DNA in patients with HNSCC. In these 5 studies (n = 411), patients had both pre- and post-treatment blood samples. The pooled sensitivity, in detecting a recurrence, was estimated to be 54% (95% CI: 32%-74%), while the pooled specificity was 98% (95% CI: 93%-99.4%). The pooled false-positive rate is 2% (95% CI: 0.6%-7%). The area under the curve (AUC) of the summary HSROC was 0.93. Positive predictive value was estimated to 93% and the negative predictive value to 94%. CONCLUSIONS: Plasma HPV-DNA is a promising tool for surveillance in patients with HPV-related HNSCC, that is, OPSCC, and has a high specificity. By recent technical advances and by increasing follow-up blood samples, the sensitivity could likely be improved.
BACKGROUND: The incidence of human papillomavirus-induced (HPV+) head and neck squamous cell carcinoma (HNSCC), that is, especially oropharyngeal cancers (OPSCC), is increasing, and a significant proportion of patients encounter disease progression. A simple and sensitive test to identify patients with progression is an unmet need. OBJECTIVE OF REVIEW: To systematically review the literature and carry out a meta-analysis of studies, investigating circulating HPV-DNA as a biomarker for disease progression in patients with HNSCC. TYPE OF REVIEW: A systematic review and meta-analysis. SEARCH STRATEGY: PubMed, EMBASE and the Cochrane Library were systematically searched for articles published in English from January 1980 to November 2017. Search terms used were related to HPV, cancer sites, blood-based biomarkers and terms for specific use settings. EVALUATION METHOD: Articles reviewed and selected by authors and data on study design, demographic variables, location, HPV status, number of pre-treatment blood tests, number of post-treatment blood tests, blood HPV status and number of recurrences and length of follow-up were extracted. A meta-analysis of HPV-DNA as a diagnostic test for recurrence by means of a hierarchical summary receiver operating curve (HSROC) model was performed. RESULTS: We identified 5 studies (n = 600 subjects) examining circulating HPV-DNA in patients with HNSCC. In these 5 studies (n = 411), patients had both pre- and post-treatment blood samples. The pooled sensitivity, in detecting a recurrence, was estimated to be 54% (95% CI: 32%-74%), while the pooled specificity was 98% (95% CI: 93%-99.4%). The pooled false-positive rate is 2% (95% CI: 0.6%-7%). The area under the curve (AUC) of the summary HSROC was 0.93. Positive predictive value was estimated to 93% and the negative predictive value to 94%. CONCLUSIONS: Plasma HPV-DNA is a promising tool for surveillance in patients with HPV-related HNSCC, that is, OPSCC, and has a high specificity. By recent technical advances and by increasing follow-up blood samples, the sensitivity could likely be improved.
Authors: Sanjana Balachandra; Samuel B Kusin; Rebecca Lee; James-Michael Blackwell; Jasmin A Tiro; Lindsay G Cowell; Cheng-Ming Chiang; Shwu-Yuan Wu; Sanskriti Varma; Erika L Rivera; Helen G Mayo; Lianghao Ding; Baran D Sumer; Jayanthi S Lea; Aditya Bagrodia; Linda M Farkas; Richard Wang; Carole Fakhry; Kristina R Dahlstrom; Erich M Sturgis; Andrew T Day Journal: Cancer Date: 2020-12-03 Impact factor: 6.860
Authors: Sarah M Dermody; Catherine T Haring; Chandan Bhambhani; Muneesh Tewari; J Chad Brenner; Paul L Swiecicki Journal: Curr Treat Options Oncol Date: 2021-02-08
Authors: G C Mayne; C M Woods; N Dharmawardana; T Wang; S Krishnan; J C Hodge; A Foreman; S Boase; A S Carney; E A W Sigston; D I Watson; E H Ooi; D J Hussey Journal: J Transl Med Date: 2020-07-10 Impact factor: 5.531